Enbrel
Biological
Amgen Inc.
Total Payments
$52.8M
Transactions
296,196
Doctors
17,129
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $654,745 | 33,441 | 4,053 |
| 2023 | $842,333 | 42,539 | 5,050 |
| 2022 | $2.1M | 42,596 | 5,871 |
| 2021 | $2.2M | 42,225 | 6,578 |
| 2020 | $2.0M | 21,334 | 3,624 |
| 2019 | $4.9M | 34,353 | 5,309 |
| 2018 | $12.9M | 39,358 | 6,148 |
| 2017 | $27.3M | 40,350 | 7,312 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.0M | 1,657 | 71.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.5M | 4,687 | 14.2% |
| Food and Beverage | $5.4M | 285,428 | 10.2% |
| Travel and Lodging | $942,237 | 3,719 | 1.8% |
| Consulting Fee | $814,102 | 371 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $226,428 | 128 | 0.4% |
| Education | $3,046 | 206 | 0.0% |
Payments by Type
Research
$38.0M
1,657 transactions
General
$14.8M
294,539 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Enbrel RA Remission Study | Amgen Inc. | $16.8M | 6 |
| Etanercept monotherapy in PsA | Amgen Inc. | $12.9M | 8 |
| P4 - Enbrel in Otezla IR (open label) | Amgen Inc. | $2.2M | 5 |
| TARGET: Treatments Against RA and Effect on FDG PET-CT | Amgen Inc. | $1.7M | 2 |
| P4 - Enbrel New Formulation Pain Comparison Study | Amgen Inc. | $986,805 | 4 |
| Monitoring nail changes in patients with psoriatic disease treated with etanercept using non-invasive Optical Coherence Tomography | Amgen Inc. | $452,548 | 0 |
| Utility of Administrative and Clinical Data to Predict Treatment Interventions in US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry | Amgen Inc. | $379,875 | 0 |
| The Immunological Basis for Treatment Resistance to Anti-TNF Therapy | Amgen Inc. | $375,657 | 0 |
| Pilot Study Evaluating the Efficacy of Etanercept in Acute Gout | Amgen Inc. | $359,792 | 0 |
| Identification of Patients with Early Sjogren's Syndrome | Amgen Inc. | $353,952 | 0 |
| The TARGET Biomarker Study: Treatments Against RA and Effect on FDG PETCT | Amgen Inc. | $240,000 | 0 |
| The TARGET Biomarker Study: Treatments Against RA and Effect | Amgen Inc. | $180,000 | 0 |
| The Impact of Biologic DMARDs on Rheumatoid Arthritis Patient Outcomes: Analysis of the BRASS Registry | Amgen Inc. | $149,175 | 0 |
| Cost of Remission and Disease Activity in Rheumatoid Arthritis Patients In United States | Amgen Inc. | $129,679 | 0 |
| Imaging and Cellular Markers of Arthritis in Psoriasis | Amgen Inc. | $94,650 | 0 |
| Analysis of Hand Radiographs during Tumor Necrosis Inhibitor TNFi Therapy in US Veterans | Amgen Inc. | $69,700 | 0 |
| The TARGET Biomarker Study: Treatments Against RA and Effect on FDG PETi CT | Amgen Inc. | $60,000 | 0 |
| Pediatric Follow Up | Amgen Inc. | $55,965 | 0 |
| Psoriasis Inflammation and Systemic Co-Morbidities: Is it Preventable or Reversible? | Amgen Inc. | $55,280 | 0 |
| Stigma, Anxiety and Depression in Children and Adolescents with Skin Disorders: A i12PAN-PeDRAi12i12 Study (IRB title: The Impact of Pediatric Skin Disorders: The i12Bigi12i12 Study) | Amgen Inc. | $50,168 | 0 |
Top Doctors Receiving Payments for Enbrel — Page 686
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Dermatology | Vestavia Hls, AL | $4.35 | 1 |
| , MSN, CRNP, FNP-C | Family | Media, PA | $4.33 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Ponce, PR | $4.32 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Port Orange, FL | $2.89 | 1 |
| , FNP | Nurse Practitioner | Brunswick, GA | $2.43 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $52.8M
Product Information
- Type Biological
- Total Payments $52.8M
- Total Doctors 17,129
- Transactions 296,196
About Enbrel
Enbrel is a biological associated with $52.8M in payments to 17,129 healthcare providers, recorded across 296,196 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $654,745 was paid across 33,441 transactions to 4,053 doctors.
The most common payment nature for Enbrel is "Unspecified" ($38.0M, 71.9% of total).
Enbrel is associated with 20 research studies, including "Enbrel RA Remission Study" ($16.8M).